FDA-Approves first Non-Immunosuppressive Therapy for FSGS Written By Dr. Kamal Kant Jakhar14 April 2026 8:45 PM ISTThe US Food and Drug Administration has granted full approval to Sparsentan for the treatment of Focal Segmental Glomerulosclerosis, marking the first...
Povetacicept Reduces Proteinuria in IgA Nephropathy, suggests trial Written By Dr. Kamal Kant Kohli9 April 2026 8:00 PM ISTPovetacicept, a dual BAFF/APRIL inhibitor, significantly lowered proteinuria in patients with immunoglobulin A nephropathy (IgAN), as demonstrated in...
Finerenone Achieves 25 Percent Greater Albuminuria Reduction in Type 1 Diabetes and CKD: FINE-ONE Study Finds Written By Aashi verma25 March 2026 8:00 AM ISTFinerenone achieves a 25% greater reduction in albuminuria compared to placebo in adults with type 1 diabetes and chronic kidney disease, a recent...
Apecotrep Shows Promise in Reducing Proteinuria in Primary FSGS in Phase 2 trial Written By Dr. Kamal Kant Kohli2 Feb 2026 9:45 PM ISTIn a multicenter, phase 2 trial across 31 centers in 10 countries, apecotrep (BI 764198) reduced proteinuria by 40% over 12 weeks in patients with...
New-Onset Proteinuria (NOP) During Hospitalization: A Critical Prognostic Marker in Atherosclerotic Cardiovascular Disease, Reports JACC Advances Written By Prem Aggarwal29 Nov 2025 11:45 AM ISTA recent study found that the presence of new-onset proteinuria during hospitalization among atherosclerotic cardiovascular disease (ASCVD) patients...
Albuminuria, Not Kidney Function, Predicts Future Cancer Risk, reveals study Written By Dr Riya Dave26 Sept 2025 8:45 AM ISTResearchers have determined in a new study that albuminuria, and not diminished kidney function, is independently associated with a greater risk of...
HCQ Shows Promise in Reducing Proteinuria in Primary Glomerular Diseases: Study Written By Dr. Shravani Dali18 Aug 2025 9:00 PM ISTA new study published in BMC Nephrology found that hydroxychloroquine (HCQ) therapy demonstrated a trend toward reducing proteinuria in patients with...
Renal Dysfunction Raises Risk of Vertebral Fractures in T2DM Patients, reveals study Written By Dr Riya Dave4 July 2025 10:00 PM ISTResearchers have demonstrated that renal impairment highly increases the risk of vertebral fracture among type 2 diabetes mellitus (T2DM) patients,...
Atacicept Significantly Reduces Proteinuria in IgA Nephropathy: Phase 3 Trial Results Dr. Kamal Kant Kohli19 Jun 2025 8:30 PM ISTResearchers have found in phase 3 ORIGIN 3 trial that investigational dual BAFF/APRIL inhibitor atacicept significantly reduced proteinuria in...
Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy Written By Ruchika Sharma3 April 2025 4:30 PM ISTEast Hanover: Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia...
Novartis oral Fabhalta secures USFDA okay for adults with C3 glomerulopathy Written By Ruchika Sharma21 March 2025 12:42 PM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the treatment...
Proteinuria Linked to Increased Risk of Atrial Fibrillation Across All Glycemic Stages: Study Finds Written By Medha Baranwal3 Feb 2025 8:00 AM ISTSouth Korea: A recent nationwide population-based cohort study has shed light on the significant relationship between proteinuria and the risk of...
